None
Quote | Precision BioSciences Inc. (NYSE:DTIL)
Last: | $ |
---|---|
Change Percent: | 3.77% |
Open: | $8.00 |
Close: | $8.26 |
High: | $8.31 |
Low: | $7.88 |
Volume: | 671,398 |
Last Trade Date Time: | 02/12/2020 04:40:53 pm |
News | Precision BioSciences Inc. (NYSE:DTIL)
2024-07-01 07:17:55 ET More on Precision BioSciences Precision BioSciences GAAP EPS of $1.70, revenue of $17.58M beats by $11.56M Read the full article on Seeking Alpha For further details see: Precision BioSciences joins Russell Microcap Index
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced its addition to the Russel...
Message Board Posts | Precision BioSciences Inc. (NYSE:DTIL)
Subject | By | Source | When |
---|---|---|---|
bulls and bears | jondoeuk | investorshub | 06/20/2023 11:13:21 AM |
$DTIL The trading | carusso | investorshub | 06/16/2023 11:12:52 AM |
$DTIL Price now | swampboots | investorshub | 06/15/2023 10:03:08 PM |
The trading up | jondoeuk | investorshub | 06/12/2023 11:00:11 PM |
$DTIL bulls and bears | jondoeuk | investorshub | 06/12/2023 4:35:07 AM |
News, Short Squeeze, Breakout and More Instantly...
Precision BioSciences Inc. Company Name:
DTIL Stock Symbol:
NYSE Market:
Precision BioSciences Inc. Website:
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced its addition to the Russel...
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, is presenting data today at the United Mit...
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced the appointment of Mark Su...